Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG-based therapy on a phase 2 trial
Targeted DNA sequencing (T200 panel) of 74 baseline bone marrow samples from patients with core binding factor acute myeloid leukemia (CBF-AML) enrolled on a phase 2 clinical trial of FLAG-based therapy. Sequencing was performed to characterize the mutational landscape of CBF-AML, including tyrosine kinase, chromatin modifier, DNA methylation, cohesin, and spliceosome pathway mutations, and to assess their impact on molecular responses and clinical outcomes. Samples were sequenced on an Illumina platform and processed through an in-house bioinformatics pipeline at The University of Texas MD Anderson Cancer Center.